ARROWHEAD PHARMACEUTICALS, INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $1.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-04
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.70M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $1.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.70M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.70M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $1.70M 10-K · filed 2025-11-25 |
| 2025-06-30 | $1.70M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.70M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $1.70M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $1.70M 10-K · filed 2024-11-26 |
| 2024-06-30 | $1.70M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.70M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.70M 10-Q · filed 2024-02-06 |
| 2023-09-30 | $1.70M 10-K · filed 2023-11-29 |
| 2023-06-30 | $1.70M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.70M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $1.70M 10-Q · filed 2023-02-06 |
| 2022-09-30 | $1.70M 10-K · filed 2022-11-28 |
| 2022-06-30 | $1.70M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.70M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.70M 10-Q · filed 2022-02-02 |
| 2021-09-30 | $1.70M 10-K · filed 2021-11-22 |
| 2021-06-30 | $1.70M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.70M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $1.70M 10-Q · filed 2021-02-04 |
| 2020-09-30 | $1.70M 10-K · filed 2020-11-23 |
| 2019-09-30 | $1.70M 10-K · filed 2019-11-25 |
| 2018-09-30 | $1.70M 10-K · filed 2018-12-11 |
| 2017-09-30 | $1.70M 10-K · filed 2017-12-12 |
| 2016-09-30 | $1.70M 10-K · filed 2016-12-14 |
| 2015-09-30 | $1.71M 10-K · filed 2015-12-14 |
| 2015-06-30 | $1.71M 10-Q · filed 2015-08-04 |
| 2015-03-31 | $1.71M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $41.90K 10-Q · filed 2015-02-09 |
| 2014-09-30 | $55.00K 10-K · filed 2014-11-25 |
| 2014-03-31 | $55.00K 10-Q · filed 2014-05-06 |
| 2013-12-31 | $55.00K 10-Q · filed 2014-02-04 |
| 2013-09-30 | $55.00K 10-K · filed 2013-12-18 |
| 2013-06-30 | $14.00K 10-Q · filed 2013-08-07 |
| 2013-03-31 | $148.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $222.00K 10-Q · filed 2013-02-13 |
| 2012-09-30 | $300.00K 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |